-
-
-
-
-
-
-
Kazia Therapeutics reports preclinical data for cancer drug NDL2
-
-
-
-
-
-
-
Kazia plans FDA meeting on glioblastoma drug regulatory pathway
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Sells IP and Trademarks Rights for Cantrixil for $1M
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Enters Licensing Agreement with QIMR Berghofer
-
-
-
-
424,107 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

